

Product Pipeline

	Phase I	Phase II	Phase III	Registration	Approval
<u>Neratinib: Tyrosine kinase inhibitor</u>					
HER2+ Breast Cancer					
Extended adjuvant <i>Neratinib monotherapy</i>					
Metastatic <i>Monotherapy or combo therapy</i>					
Metastatic HER2 amplified/mutated <i>Combo with trastuzumab deruxtecan</i>					
<u>Alisertib: Aurora kinase A inhibitor</u>					
HRc+*** HER2-negative MBC					
Metastatic EGFR-mutant NSCLC****					
Small cell lung cancer					

*

